Clinical Trial Update: BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of BGJ398 (infigratinib) for FGFR-positive recurrent head and neck cancer was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Carcinoma
• Head and Neck Squamous Cell Carcinoma
• Nasopharyngeal Carcinoma
• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• BGJ398 (BGJ398)

Snippet

Sponsor: University of Chicago | Conditions: FGFR Gene Amplification, FGFR1 Gene Amplification | Phase 2 | Status: TERMINATED | Results posted: 2019-04-10